Investors gain exposure to three distinct but complementary businesses: ZenGUARD, Triera Biosciences and Albany Graphite., We allocate capital and expertise based on risk‑adjusted return potential.
Why Invest in Zentek?
Zentek offers a differentiated investment profile with exposure to new disruptive products, therapeutic development and critical minerals:
- One platform, three brands –ZenGUARD, Triera and Albany.
- IP‑rich, asset‑light model – Focus on intellectual property, partnerships and licensing, complemented by a high‑potential mineral asset.
- Multiple paths to value – Revenue from products and services, non‑dilutive funding and grants, strategic partnerships, potential spin‑outs, offtake and royalty structures.
- Quality and execution focus – ISO‑certified quality management system and a dedicated manufacturing facility support commercialization of regulated products.
Our Portfolio
ZenGUARD
ZenGUARD™ is Zentek’s patented technology platform. Utilizing the revolutionary benefits of the carbon-based nanomaterial graphene, ZenGUARD™ is a technology that can be easily applied to materials to enhance their viral filtration efficiency.
ZenGUARD transforms simple, critical items like surgical masks and other products into high‑performance protective tools without changing how people use them.
Triera Biosciences
Wholly owned aptamer‑based therapeutics platform, built on an exclusive licence, pursuing infectious‑disease and other high‑value indications with a partnering‑first model.
Albany Graphite
High‑purity, igneous‑hosted graphite deposit in Northern Ontario, being advanced as a strategic North American source of ultra‑high purity graphite for EV batteries, nuclear and advanced materials.
Financials and Investor Resources
Zentek provides regular financial disclosure in line with public‑company reporting requirements.
You can find:
- Quarterly and annual financial statements and MD&A.
- Annual Information Form and other regulatory filings.
- Shelf prospectuses, offering documents and circulars where applicable.
These documents are intended to help investors assess Zentek’s financial position, capital structure and progress across its brands.
Investor Resources
For further information:
Capital Allocation and Strategy
Zentek’s capital allocation aims to balance near‑, medium‑ and long‑term value creation.
- Prioritize resources for ZenGUARD to support regulatory approvals, commercialization and partnership‑driven growth in filtration and PPE.
- Fund Triera selectively through a combination of internal capital and non‑dilutive funding, with the goal of platform validation and co‑development deals.
- De‑risk Albany Graphite through targeted technical programs and external funding, while preserving strategic flexibility for spin‑out, JV, offtake or royalty options.
The company’s goal is to grow intrinsic value per share over time by advancing each brand while managing portfolio risk and dilution.
Stay Informed
Investors can stay up to date on Zentek by:
- Following news releases and corporate updates.
- Reviewing the latest corporate presentation.
- Subscribing to investor email updates or contacting Investor Relations directly.
- For further information:
Investor Relations
investorrelations@zentek.com